Page last updated: 2024-11-12
vialinin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
vialinin A: free radical scavenger from an edible mushroom in China; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11563133 |
| CHEMBL ID | 2012938 |
| MeSH ID | M0496101 |
Synonyms (15)
| Synonym |
|---|
| 858134-23-3 |
| vialinin a |
| CHEMBL2012938 |
| bdbm50437693 |
| 1,1'-(4,4'',5',6'-tetrahydroxy[1,1':4',1''-terphenyl]-2',3'-diyl) benzeneacetic acid ester |
| 4,4'',5',6'-tetrahydroxy[1,1':4',1''-terphenyl]-2',3'-diyl ester benzeneacetic acid |
| NOJUKCRPSUMHQQ-UHFFFAOYSA-N |
| gtpl8669 |
| [3,4-dihydroxy-2,5-bis(4-hydroxyphenyl)-6-(2-phenylacetyl)oxyphenyl] 2-phenylacetate |
| AKOS024458452 |
| DTXSID00468621 |
| Q27089142 |
| terrestrin a |
| HY-103435 |
| CS-0027883 |
Research Excerpts
Overview
Vialinin A is an extract from mushroom and is a specific USP4 inhibitor. It is an extremely potent inhibitor against tumor necrosis factor (TNF)-α production in rat basophilic leukemia (RBL-2H3) cells.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | IC50 (µMol) | 22.3000 | 3.0000 | 5.0667 | 6.8000 | AID761505 |
| Ubiquitin carboxyl-terminal hydrolase 5 | Homo sapiens (human) | IC50 (µMol) | 5.9000 | 3.0000 | 4.4500 | 5.9000 | AID761509 |
| Ubiquitin carboxyl-terminal hydrolase 5 | Homo sapiens (human) | Ki | 8.2500 | 4.0000 | 4.0000 | 4.0000 | AID761507; AID761509 |
| Ubiquitin carboxyl-terminal hydrolase 4 | Homo sapiens (human) | IC50 (µMol) | 1.5000 | 1.5000 | 1.5000 | 1.5000 | AID761508 |
| Sentrin-specific protease 1 | Homo sapiens (human) | IC50 (µMol) | 1.7650 | 0.0064 | 2.6446 | 6.1000 | AID1637028; AID1637029 |
| Sentrin-specific protease 1 | Homo sapiens (human) | Ki | 1.0000 | 0.9300 | 1.0000 | 1.0700 | AID1637030; AID1637031 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (30)
Molecular Functions (15)
Ceullar Components (12)
Bioassays (29)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID761496 | Inhibition of cathepsin B (unknown origin) at 6.3 uM after 20 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761508 | Inhibition of human USP4 using Ub-AMC as substrate after 60 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID654111 | Antiinflammatory activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced TNF-alpha production preincubated for 15 mins prior DNP-BSA challenge measured after 30 mins by ELISA | 2012 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7 | Design and synthesis of a vialinin A analog with a potent inhibitory activity of TNF-α production and its transformation into a couple of bioprobes. |
| AID1126481 | Inhibition of DNP-BSA-stimulated TNF-alpha production in rat RBL2H3 cells preincubated for 15 mins followed by DNP-BSA addition measured after 3 hrs by ELISA | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8 | Structural elucidation and synthesis of vialinin C, a new inhibitor of TNF-α production. |
| AID761515 | Competitive binding affinity to human USP5 C335A mutant by SDS-PAGE analysis in presence of biotin-DMT | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID1637032 | Inhibition of SENP1 in human KU812 cells preincubated for 20 mins followed by addition of HA-SUMO1-VS as substrate measured after 2 hrs by immunoblot analysis | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID654112 | Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by spectrophotometry | 2012 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7 | Design and synthesis of a vialinin A analog with a potent inhibitory activity of TNF-α production and its transformation into a couple of bioprobes. |
| AID1637027 | Inhibition of TNF-alpha production in mouse bone marrow-derived mast cells measured after 15 mins by ELISA | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID761504 | Inhibition of human USP2 using Ub-AMC as substrate at 1 to 30 uM after 60 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID1637030 | Binding affinity to recombinant human 6His-tagged SENP1 catalytic domain expressed in Escherichia coli | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID761509 | Inhibition of wild type human USP5 expressed in Escherichia coli BL21(DE3) using Ub-AMC as substrate after 60 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761503 | Inhibition of human USP8 using Ub-AMC as substrate at 1 to 30 uM after 60 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID1637031 | Binding affinity to full-length recombinant human 6His-tagged SENP1 expressed in Escherichia coli BL21 (DE3) | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID761513 | Competitive binding affinity to human USP5 C335A/H818A mutant by SDS-PAGE analysis in presence of biotin-DMT | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761512 | Inhibition of wild type human USP5 expressed in Escherichia coli BL21(DE3) using K48-linked tetraubiquitin as substrate assessed as substrate hydrolysis at 10 uM after 15 mins by SDS-PAGE analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761497 | Inhibition of calpain1/2 (unknown origin) using Suc-LLVY-AMC as substrate at 6.3 uM after 20 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761507 | Competitive inhibition of wild type human USP5 expressed in Escherichia coli BL21(DE3) using Ub-AMC as substrate | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761520 | Inhibition of TNF-alpha production in rat RBL2H3 cells after 16 hrs by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID1851299 | Inhibition of TNF-alpha production in rat RBL-2H3 cells | 2022 | Bioorganic & medicinal chemistry, 09-15, Volume: 70 | Anti-inflammatory and anticancer p-terphenyl derivatives from fungi of the genus Thelephora. |
| AID1637026 | Inhibition of TNF-alpha production in antigen-stimulated rat RBL2H3 cells measured after 15 mins by ELISA | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID1637028 | Inhibition of recombinant human 6His-tagged SENP1 catalytic domain expressed in Escherichia coli preincubated for 15 mins followed by addition of SUMO1-AMC as substrate measured after 1 hr by fluorescence analysis | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID1637029 | Inhibition of full-length recombinant human 6His-tagged SENP1 expressed in Escherichia coli BL21 (DE3) preincubated for 15 mins followed by addition of SUMO1-AMC as substrate measured after 1 hr by fluorescence analysis | 2016 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17 | Vialinin A and thelephantin G, potent inhibitors of tumor necrosis factor-α production, inhibit sentrin/SUMO-specific protease 1 enzymatic activity. |
| AID1851302 | Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs | 2022 | Bioorganic & medicinal chemistry, 09-15, Volume: 70 | Anti-inflammatory and anticancer p-terphenyl derivatives from fungi of the genus Thelephora. |
| AID761505 | Inhibition of human UCH-L1 using Ub-AMC as substrate after 60 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761506 | Inhibition of human UCH-L3 using Ub-AMC as substrate at 1 to 30 uM after 60 mins by fluorometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID1126480 | Inhibition of TNF-alpha production in rat RBL2H3 cells | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8 | Structural elucidation and synthesis of vialinin C, a new inhibitor of TNF-α production. |
| AID761516 | Competitive binding affinity to human recombinant USP5 after 1 hr by SDS-PAGE analysis in presence of biotin-DMT | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761514 | Competitive binding affinity to human USP5 H818A mutant by SDS-PAGE analysis in presence of biotin-DMT | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| AID761519 | Binding affinity to USP5 in rat RBL2H3 cell extracts at 10 to 40 uM by SDS-PAGE analysis | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Vialinin A is a ubiquitin-specific peptidase inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.47) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (94.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||